Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials-Reference-Cited by-同舟云学术

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials

Published:2017-04 Issue:4 Volume:4 Page:e176-e182
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Smith Sonali M,Pitcher Brandelyn N,Jung Sin-Ho,Bartlett Nancy L,Wagner-Johnston Nina,Park Steven I,Richards Kristy L,Cashen Amanda F,Jaslowski Anthony,Smith Scott E,Cheson Bruce D,Hsi Eric,Leonard John P

Funder

National Cancer Institute of the National Institutes of Health

Publisher

Elsevier BV

Subject

Hematology

Reference25 articles.

1. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma;Habermann;Br J Haematol,2009

2. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study;Goy;J Clin Oncol,2013

3. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma;Witzig;J Clin Oncol,2009

4. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance);Leonard;J Clin Oncol,2015

5. CALGB 50803 (Alliance): a phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma;Martin;Proc Am Soc Clin Oncol,2014

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenalidomide, rituximab (R ² ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma;Leukemia & Lymphoma;2024-03-08

2. Genetic landscape and prognostic value of IRF4 alterations in Diffuse large B-cell lymphoma patients;2024-02-07

3. Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects;Critical Reviews in Oncology/Hematology;2023-10

4. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia;Expert Opinion on Drug Metabolism & Toxicology;2023-09-02

5. Recent advances in treatment of nodal and gastrointestinal follicular lymphoma;World Journal of Gastroenterology;2023-06-21